ANTI-ANGINAL GUIDELINES NEED NOT AGREE WITH EC DRAFT, ADVISORY COMMITTEE SAYS; RECOMMENDS WORKSHOP TO DETERMINE EARLY STAGE ISSUES IN DRUG DEVELOPMENT